International Conference and Exhibition on Nanomedicine and Drug Delivery May 29-31, 2017 Osaka, Japan

ConferenceSeries Ltd is a renowned organization that organizes highly notable Pharmaceutical Conferences throughout the globe. Currently we are bringing forth “International Conference on Nanomedicine and Drug Delivery” (NanoDelivery 2017) scheduled to be held during May 29-31, 2017 at Osaka, Japan. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Nanomedicine and Drug Delivery.

ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

2017 Highlights:

• 300+ Participation (70 Industry: 30 Academia)
• 10+ Keynote Speakers
• 50+ Plenary Speakers
• 20+ Exhibitors
• 14 Innovative Educational Sessions
• 5+ Workshops
• B2B Meetings

Nanomedicine and drugdelivery will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nano medicine and drug delivery respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as Japan, China, India and other economies in the region. Japan is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.This conference seeks to showcase work in the area of Nanomedicine, Drug Delivery Systems, and nanotechnology, Nanobiothechnology, particularly related to drug delivery.  

For More PS: http://nanomedicine.pharmaceuticalconferences.com/

(Click here for any queries)

Nanomedicine and drugdelivery can address one of the greatest challenges in the post-genomic era of the 21st century – making the essential connections between Academics and industry professionals.

To meet these challenges, the field of Nanomedicine and drugdelivery has undergone exponential growth during the last 5 years. Technologies such as Personalized Nanomedicine, Nanomedicine in Theranostics,  Design of Nanodrugs, Synthesis of Nanoparticles for Drug Delivery, Regenerative Medicine and Tissue Engineering, Nanomedicines and Biomedicalapplications, Nanomaterials  for drug delivery, Regulatory Aspects Towards Approval of Nanomedicine, NanoPharmaceutical Industry and Market processing and drug delivery promise to transform the world of nanomedicines and drug delivery much in the same way that integrated a transformed the world of pharmaceutical sciences.

Nanodelivery 2017 has everything you need:

Open panel discussions: Providing an open forum with experts from academia and business to discuss on current challenges in nanomedicine and drugdelivery, where all attendees can interact with the panel followed by a Q&A session.

Speaker and poster presentations: Providing a platform to all academicians and industry professionals to share their research thoughts and findings through a speech or a poster presentation.

Editorial board meeting: Discussing on growth and development of open access Nanomedicine and drugdelivery International Journals and recruiting board members and reviewers who can support the journal.

Round table meetings: Providing a platform where industry professionals meet academic experts.

Over 50+ organizations and international pavilions will be exhibiting at the Nanodelivery 2017 conference and Exhibition. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will see at the Nanodelivery Exhibition, you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

The Nanodelivery 2017 has everything you need, all under one roof, saving you both time and money.   It is the event you cannot afford to miss!

Who's Coming to Nanodelivery 2017?

• CEOs / CMOs                                                          
• CTOs  
• VPS, Directors, & Managers
• World top Ranked Scientists                           
• Researchers                                                            
• Universities
• Medical Devices
• Pharmaceuticals companies
• Tool and Materials companies
• ... and more!                                                       

Organizing committee Members of Nanodelivery 2017:

• Diane J. Burgess, University of Connecticut, USA
• Roger M. Leblanc, University of Miami, USA
• Vladimir Torchilin, Northeastern University, USA
• Volkmar Weissig, President of World Mitochondria, Midwestern University, USA
• Roberto De Santis, IPCB-CNR Institute of Polymers, ITALY
• Hidetoshi Arima, Kumamoto University, JAPAN
• Kun Cheng, University of Missouri-Kasas City, USA
• Vincenzo Guarino, IPCB-CNR Institute of Polymers, ITALY

PS: http://nanomedicine.pharmaceuticalconferences.com/organizing-committee.php

(Click here to request to JOIN with Organizing committee Member)

Dear participants of Nano Delivery 2017!

Welcome to Osaka, Japan, to participate in Nano Delivery 2017, International Conference and Exhibition on Nanomedicine and Drug Delivery. This conference will continue the line of highly successful recent conferences on Pharmaceutics and Drug Delivery taking place all over the globe.

Nano Delivery 2017 should serve as a platform for the interaction between experts in the areas of nanotechnology, nanomedicine, pharmaceutics and drug delivery around the world and aims in sharing some unique research and translational studies on various advances in the field of Nanomedicine and Drug Delivery Technologies. The main theme of the conference is designated as “Challenges and Innovations in Nanomedicine and Drug Delivery Research”, which opens the doors for many researchers, clinicians, and industry representatives working is these exciting areas. It is expected to bring together both reputable scientists in advanced stages of their career and young researches from many related disciplines. The conference expects many new ideas to emerge at the interfaces between disciplines aiming to solve the most important problems relating to the health and wellbeing of the humanity.

The conference will take place in Osaka, one of the main Japanese cities, an important site for pharmaceutical science and industry and just a great place to visit.

With our warmest regards, the Organizing Committee of the Nano Delivery wishes you the most productive work and the most pleasant stay in Osaka.

Dr. Vladimir Torchilin,

Director, Center for Pharmaceutical Biotechnology and Nanomedicine

Editor-in-Chief, Drug Delivery Editor-in-Chief,

Current Drug Discovery Technologies Editor-in-Chief, OpenNano

Northeastern University, USA

International Conference and Exhibition on Nanomedicine and Drug Delivery May 29-31, 2017 Osaka, Japan

ConferenceSeries Ltd is a renowned organization that organizes highly notable Pharmaceutical Conferences throughout the globe. Currently we are bringing forth “International Conference on Nanomedicine and Drug Delivery” (NanoDelivery 2017) scheduled to be held during May 29-31, 2017 at Osaka, Japan. The conference invites all the participants across the globe to attend and share their insights and convey recent developments in the field of Nanomedicine and Drug Delivery.

ConferenceSeries Ltd organizes a conference series of 1000+ Global Events inclusive of 1000+ Conferences, 500+ Upcoming and Previous Symposiums and Workshops in USA, Europe & Asia with support from 1000 more scientific societies and publishes 700+ Open access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

2017 Highlights:

• 300+ Participation (70 Industry: 30 Academia)
• 10+ Keynote Speakers
• 50+ Plenary Speakers
• 20+ Exhibitors
• 14 Innovative Educational Sessions
• 5+ Workshops
• B2B Meetings

Nanomedicine and drugdelivery will account for 40% of a $136 billion nanotechnology-enabled drug delivery market by 2021. We forecast the total market size in 2021 to be US$136 billion, with a 60/40 split between nano medicine and drug delivery respectively, although developing new targeted delivery mechanisms may allow more value to be created for companies and entrepreneurs.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as Japan, China, India and other economies in the region. Japan is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.This conference seeks to showcase work in the area of Nanomedicine, Drug Delivery Systems, and nanotechnology, japan nanotechnology, Nanobiothechnology, particularly related to drug delivery.  

For More PS: http://nanomedicine.pharmaceuticalconferences.com/

(Click here for any queries)

Nanomedicine and drugdelivery can address one of the greatest challenges in the post-genomic era of the 21st century – making the essential connections between Academics and industry professionals.

To meet these challenges, the field of Nanomedicine and drugdelivery has undergone exponential growth during the last 5 years. Technologies such as Personalized Nanomedicine, Nanomedicine in Theranostics,  Design of Nanodrugs, Synthesis of Nanoparticles for Drug Delivery, Regenerative Medicine and Tissue Engineering, Nanomedicines and Biomedicalapplications, Nanomaterials  for drug delivery, Regulatory Aspects Towards Approval of Nanomedicine, NanoPharmaceutical Industry and Market processing and drug delivery promise to transform the world of nanomedicines and drug delivery much in the same way that integrated a transformed the world of pharmaceutical sciences.

Nanodelivery 2017 has everything you need:

Open panel discussions: Providing an open forum with experts from academia and business to discuss on current challenges in nanomedicine and drugdelivery, where all attendees can interact with the panel followed by a Q&A session.

Speaker and poster presentations: Providing a platform to all academicians and industry professionals to share their research thoughts and findings through a speech or a poster presentation.

Editorial board meeting: Discussing on growth and development of open access Nanomedicine and drugdelivery International Journals and recruiting board members and reviewers who can support the journal.

Round table meetings: Providing a platform where industry professionals meet academic experts.

Over 50+ organizations and international pavilions will be exhibiting at the Nanodelivery 2017 conference and Exhibition. Exhibitors will include equipment manufacturers and suppliers, systems providers, finance and investment firms, R&D companies, project developers, trade associations, and government agencies.

In addition to the products and services you will see at the Nanodelivery Exhibition, you will have access to valuable content, including Keynote Presentations, Product Demonstrations and Educational Sessions from today’s industry leaders.

The Nanodelivery 2017 has everything you need, all under one roof, saving you both time and money.   It is the event you cannot afford to miss!

Who's Coming to Nanodelivery 2017?

• CEOs / CMOs                                                          
• CTOs  
• VPS, Directors, & Managers
• World top Ranked Scientists                           
• Researchers                                                            
• Universities
• Medical Devices
• Pharmaceuticals companies
• Tool and Materials companies
• ... and more!                                                       

Organizing committee Members of Nanodelivery 2017:

• Diane J. Burgess, University of Connecticut, USA
• Roger M. Leblanc, University of Miami, USA
• Vladimir Torchilin, Northeastern University, USA
• Volkmar Weissig, President of World Mitochondria, Midwestern University, USA
• Roberto De Santis, IPCB-CNR Institute of Polymers, ITALY
• Hidetoshi Arima, Kumamoto University, JAPAN
• Kun Cheng, University of Missouri-Kasas City, USA
• Vincenzo Guarino, IPCB-CNR Institute of Polymers, ITALY

PS: http://nanomedicine.pharmaceuticalconferences.com/organizing-committee.php

(Click here to request to JOIN with Organizing committee Member)

Summary of Nano Delivery 2017 Conference:

Nano Delivery 2017 is an emerging field of engineering and life sciences that promises to revolutionize medicine and medical technology. There are numerous applications of nanomedicine and nanotechnology in medicinal diagnostics. These include improved imagining of the human (or any) body and detecting tumors that are only a few cells in size.

The idea that pharmaceutical agents should be delivered specifically to diseased cells holds the promise of a variety of benefits. The promise of individualized medicine is that it is efficient. Targeted drug-delivery allows doctors and patients to benefit from small dosages at just the right place and thus from fewer side effects.

Nanomedicine has therapeutic uses as well. Nanotechnology is capable of delivering medication to the exact location where they are needed, hence lesser side effects. It can also be used to destroy harmful organisms or cancer cells by interrupting their division process. Nanoprobes can be made to generate radiation that could kill bacteria, viruses and cancer cells. Nanotechnology also theoretically allows the mimicking of natural biological processes, e.g. repair of damaged tissues or acting as artificial red blood cells to transport oxygen.

The global market for healthcare nanotechnology is expected to reach USD 196.02 billion by 2020 growing at a CAGR of 12.1%, according to a new study by Grand View Research, Inc. Increasing susceptibility of patients towards chronic diseases such as cardiovascular, neurological, oncology and respiratory diseases coupled with increasing R&D spending opening new application avenues is expected to drive market growth over the next six years. Other drivers of this market include increasing government and private sector R&D aid and new players entering the market to bridge the gap between supply and demand.

Importance & Scope of Nano Delivery:

Researchers are developing a nanoparticle that can be taken orally and pass through the lining of the intestines into the bloodsteam. This should allow drugs that must now be delivered with a shot to be taken in pill form. The researchers have demonstrated the technique with lab mice so far.

Researchers are also developing a nanoparticle to defeat viruses. The nanoparticle does not actually destroy viruses molecules, but delivers an enzyme that prevents the reproduction of viruses molecules in the patients bloodstream. The effectiveness of the technique has been demonstrated in lab tests.

Nanomedicine Market in Japan:

Nanomedicine is a promising sub-segment in medicine that took off in the 1980s with the first generation of developed nanopharmaceuticals. With the use of nanotechnology, drugs can be delivered in ways not experienced so far.U.S. is a strong actor in this field with many patents having commercialized several nanopharmaceuticals.

The global nanomedicine market was valued at US$50.1 billion in 2011 and is projected to grow to US$96.9 billion in 2016. The share of nanomedicine to the total global pharmaceutical market is estimated at 5.3 percent in 2011 indicating its niche character presently.

In Japan, for various reasons, the nanomedicine market size in terms of the total market is much smaller. A rough estimate shows that the share is between 1 to 2 percent corresponding to approximately US$1 to 2 billion. A limited number of approved Japanese nanodrugs together with a long time until approved foreign products entered the Japanese market have seemingly slowed the market expansion.

Japan = World's 2nd largest pharmaceutical market!

• Japan is the 2nd largest pharmaceutical market in the world, marking JPY 10 trillion (USD 84.4 billion) in ethical drug in 2016.
• Nikkei Stock Average has been continuously increasing since mid October, 2016.
• The government is to ease the regulations to develop new medicines for intractable diseases by shortening 5 years of drug development time.
• Japan hugely depends on imported pharmaceutical products. The annual import value in Japan was JPY 1.94 trillion (USD 16 billion) in 2015 compared to the export value of JPY 0.32 trillion (USD 2.7 billion).

• Unit: US$ billion
  Source: Japan Pharmaceutical Manufacturers Association “Data Book　2016”

Japan’s pharmaceutical industry is the world’s second largest market, after U.S., valued at US$112.1 billion in 2012 or 11.6 percent of the world market. Historically, the market has been protected from foreign competition. These days, however, deregulation has prompted investment from abroad and increased the presence of foreign companies. The pharmaceutical industry is one of the few industrial sectors in which Japan has a trade deficit. Japan imports more than two times what it exports. The rapid aging of the population and the weak global competitiveness of domestic companies are contributing factors to the trade deficit.

Japan Nanomedicine Market Size:

There is no market information available on the size of Japan’s nanomedicine market published by any of the large Japanese market research companies. Table 2 below tries to estimate the market size. The global nanomedicine market was estimated to be about 5 percent of the global pharmaceutical market in 2010 and 2011. In case of Japan, this ratio is much lower compared to the global nanomedicine market. A rough estimate indicates that the market size was approximately 1-2 percent of the Japanese pharmaceutical market in 2011-2012, or roughly between US$1 billion – US$2 billion. The drug lag of imported nanopharmaceuticals (explained in section 3.5.) is one cause of this. Nanomedicines have not been defined in Japan and are regulated within the general framework of the Pharmaceutical Affairs Law (PAL) on a product-by-product basis (20).

Approved Nanopharmaceutical Products by Application:

As there is no specific definition for drug and device (nanocarrier) combinations, they are regulated as drugs or medical devices according to their main function or purpose (20).

Pharmaceuticals are classified as nanomedicine by their sizes, i.e. materials in the submicron range.Information on marketed nanopharmaceuticals in Japan comes from various sources (21) including “Current Initiatives in Japan for Nanomedicines”, Kumiko Sakai-Kato, Toru Kawanishi, 2011, National Institute of Health Sciences (NIHS) and Ministry of Health, Labour and Welfare (MHLW) (22).

Government Pushing for Change:

order to reduce the time span from discovery and innovation to commercialization, the importance to establish open user facility networks to promote the integration of dissimilar fields and academic-industry collaboration is emphasized.

It is apparent that the government is aiming at more concrete and speedy results for R&D. Issue-driven innovation based on “exit-oriented” R&D is targeted to impact the competitive power of related industries.

A report by the Japan Science & Technology Agency titled “Japan’s New Science and Innovation Policy – Beyond the Boundaries for Innovation”, published in 2016 (50) lists up the time span for selected target applications of nanomedicine, such as:

• Molecular imaging (2015-2020)
• Integrated system of drug delivery, diagnosis and treatment (2015-2020)
• Implant devices for diagnosis and treatment (2020-2030)
• Nano-cell surgery (2020-2030)
• 3D-imaging in cells (2020-2030)

These are quite ambitious targets showing the directions where R&D will be focused.

In addition to the latest basic plan, there are other signals that the government is increasingly prioritizing innovative medicine. For instance, The Ministry of Health, Labour and Welfare will jointly with the European Union (EU) promote the development of nano-based block copolymer micelles. Together with European Medicines Agency (EMA) the ministry has released a reflection paper (February 2013) emphasizing that such micelles are able to preferentially accumulate in solid tumors (51).

Nanomedicine – Research and Development in Japan:

• University of Tokyo
• Hokkaido University
• Osaka Prefecture University
• Osaka University
• Tohoku University
• National Institute for Materials Science

The Japanese Nanomedicine Industry:

Nanomedicine start-ups and small-medium enterprises have driven the innovation process, not only in US and Europe but also in Japan. The commercialization of nanopharmaceuticals have basically followed three types of business models (67), such as:

• Development of a nanotechnology platform used to add value to second-party products
• Development and manufacturing of high-value materials for the pharmaceutical industry
• Development of nanotechnology-improved pharmaceuticals or medical devices

The majority of start-ups has adopted the third business model utilizing nanotechnology to develop own proprietary product pipelines. Often such companies introduce new or standard drugs that are delivered with a drug delivery system. Then they try to team up with pharmaceutical companies that take the products through the clinical trials.

• NanoCarrier Co., Ltd.
• LTT Bio-Pharma Co., Ltd.
• Mebiopharm Co., Ltd.
• Nippon Kayaku Co., Ltd
• Kowa Company Ltd.
• Mitsubishi Tanabe Pharma Corporation
• Taisho Pharmaceutical Co., Ltd.
• Astellas Pharma Inc
• Kaken Pharmaceutical Co., Ltd.

Pharmaceutical Regulations in Japan:

Manufacturing, importation, and sales of drugs and medical devices are regulated by the Pharmaceutical Affairs Law (PAL) of Japan.

All manufacturing and marketing applications in Japan for drugs and devices are reviewed by the Pharmaceutical and Medical Devices Agency (PMDA) (83). All applications are thoroughly reviewed before PMDA submits an approval recommendation to the Ministry of Health, Labour and Welfare (MHLW).

Under PAL, when importing to Japan and selling pharmaceutical products manufactured in other countries, a license for marketing authorization is required. The Marketing Authorization Holder (MAH) will be the owner of the license for marketing authorization.

The MAH must be based in Japan and can be the foreign company’s Japan office, the foreign company’s distributor, or an independent third party acting as the Designated Marketing Authorization Holder (DMAH).

To import and market a new drug in Japan, an approval (marketing approval) will be necessary. And the approval must be held by the Marketing Authorization Holder.

A foreign manufacturer intending to manufacture drugs in foreign countries and export them to Japan, is required to be accredited by MHLW as an “Accredited Foreign Manufacturer” (84). And it is necessary to obtain accreditation for each foreign factory location at which pharmaceuticals for export are manufactured.

The appointed MAH will be responsible for the labelling and advertising of the pharmaceuticals in Japan. As stipulated in PAL, the manufacturer’s/seller’s address, name of product, production indication, name of ingredients, expiration, etc., must be printed on the container of drugs.

Overall research in various disciplines:

The North American nanomedicine market held the majority of global market share in 2012 because of the rapidly growing nanomedicine market in the Asia-Pacific, Latin American and African region, presence of large number of patented nanomedicine products and favorable regulatory framework in the region. In addition, the presence of sophisticated healthcare infrastructure supports development of advanced products such as nano probes, nanorobots, monoclonal antibody based immunoassays and nanoparticle based imaging agents for early detection of diseases.

However, the Asia-Pacific region is expected to grow at a faster CAGR owing to presence of high unmet healthcare needs, research collaborations and increase in nanomedicine research funding in emerging economies such as China, India and other economies in the region. China is expected to surpass the United States in terms of nanotechnology funding in the near future, which indicates the growth offered by this region.

Major Nano Delivery Associations around the Globe:

• American Nano Society
• European Biotechnology Thematic Network Association
• Society for Biomaterials
• Nano Canadian Society
• American Academy of NanoMedicine
• American Association for the Advancement of Science
• Nanometer-Scale Science and Technology Division of the American Vaccum Society
• NanoScience and Technology Institute
• ASME NanoTechnology Institute
• Foresight Nanotech Institute
• International Association of NanoTechnology
• The Institute of NanoTechnology
• Microscopy Society of America
• Nano Business Alliance
• European NanoTechnology Gateway
• Scottish Center for NanoTechnology in Construction Materials
• Royal Society-NanoTechnology and NanoScience
• Czech NanoTechnology Industries Association
• Erwin Schrodinger Society for NanoSciences
• Innovationsallianz Carbon NanoTubes
• NanoTechnologies for Tommorow's Society
• American Association for the Advancement of Science

Companies involved in Nano Delivery:

USA

• Oncolytics Biotech
• Bristol-Myers Squibb
• GlaxoSmithKline
• Bend Research
• Pfizer
• BioDelivery Sciences
• GE Healthcare
• Mallinckrodt plc
• Nanosphere Inc., USA
• Pfizer Inc., USA
• Merck & Co Inc., USA
• Celgene Corporation, USA
• CombiMatrix Corporation, USA
• Abbott Laboratories
• Many Major companies in the Nano Delivery market.

Global

• PolyActivaUnilife
• Mati Therapeutics
• Formac Pharmaceuticals
• Battelle
• Toxikon
• Novartis